|
|
|
14.11.25 - 18:36
|
Merck to Buy Cidara in $9.2B Deal as Patent Deadline Looms (Bloomberg)
|
|
|
Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug Keytruda.
Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday's closing price, for a total transaction value of about $9.2 billion, the companies said Friday in a statement. Bloomberg's Madison Muller joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)...
|
|
|
|
|
|
|
14.11.25 - 13:42
|
Merck To Acquire Cidara For $221.50/shr (AFX)
|
|
|
KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Cidara Therapeutics, Inc. (CDTX) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per s......
|
|
|
|
|
|
|
14.11.25 - 07:36
|
Paukenschlag: Merck & Co vor dem nächsten Übernahme-Coup? (Der Aktionaer)
|
|
|
Nach der erfolgreichen milliardenschweren Übernahme von Verona Pharma scheint sich der US-amerikanische Pharma-Riese Merck & Co das nächste größere Akquisitionsziel ausgeschaut zu haben. Laut einem Bericht der Financial Times (FT) zufolge hat das Unternehmen ein Auge auf Cidara Therapeutics geworfen....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 12:54
|
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) (Business Wire)
|
|
|
Strategic financing to advance development of sac-TMT while Merck continues to progress its broad and expansive pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (“Blackstone”) for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), a protein found on the surface of various cancer cells. Merck is currently evaluating sac-TMT in 15 global Phase 3 clinical trials spanning six tumor types, including breast, endometrial and lung cancers.
“This agreement positions Merck to harness the potential of sac-TMT, a promising ADC candidate targeting TROP2, while we continue to advance our broad and expansive pipeline,” said Caroline Litchfield, chief financial officer, Merck. “We are making important investments to drive patient ...
|
|
|
31.10.25 - 09:45
|
Merck-Aktie: Darum ist sie besser als der Kurs es zeigt! (Sharedeals)
|
|
|
Die erste Kursreaktion nach den Quartalszahlen des Pharmakonzern Merck & Co. fiel negativ aus. Doch besitzt das Unternehmen Wachstumstreiber, deren Wert es anzuerkennen gilt. Quartalszahlen über Erwartungen Merck meldete für das dritte Quartal einen Umsatz von 17,3 Milliarden US-Dollar, ein Plus von 9,4 Prozent gegenüber dem Vorquartal. Treiber waren vor allem das Segment Animal Health […]
The post Merck-Aktie: Darum ist sie besser als der Kurs es zeigt! first appeared on sharedeals.de....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
